Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29493102 | 0.85 | AR (0.52) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL22501505 | 0.85 | AR (0.52) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL21266267 | 0.84 | GRM4 (0.52) | ALDH1A1 | |
| SCHEMBL21889640 | 0.81 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL19332363 | 0.79 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL23082190 | 0.79 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL25063497 | 0.78 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL24890524 | 0.78 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL21889763 | 0.77 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL19347009 | 0.76 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114075206-B | Novel condensed ring compound and application thereof in medicines | 广东东阳光药业股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-113493441-B | Novel spiro compound and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | EMORY UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2023-02-23 | — | — | US | disclosed |
| CN-109153640-B | Eliminating hepatitis B virus with antiviral agent | 埃默里大学 | 2022-10-28 | — | — | CN | disclosed |
| CN-114075206-A | Novel fused ring compound and application thereof in medicines | 广东东阳光药业有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-113493441-A | Novel spiro compound and application thereof in medicines | 广东东阳光药业有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-113166115-A | Monomeric and multimeric anti-HBV agents | 埃默里大学 | 2021-07-23 | — | — | CN | disclosed |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-04-22 | — | — | US | disclosed |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-04-22 | — | — | US | disclosed |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | EMORY UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | EMORY UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2020072955-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | EMORY UNIVERSITY (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2019-08-08 | — | — | US | disclosed |
| EP-3426633-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | Emory University (US) | 2019-01-16 | — | — | EP | disclosed |
| CN-109153640-A | Hepatitis type B virus is eliminated with antivirotic | 埃默里大学 | 2019-01-04 | — | — | CN | disclosed |
| WO-2017156255-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156255-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241514-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
| US-20210114981-A1 | ELIMINATION OF HEPATITIS B VIRUS WITH ANTIVIRAL AGENTS | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
| US-20230056135-A1 | MONOMER AND MULTIMERIC ANTI-HBV AGENTS | HAVCR2, HMBS, HDGF | RAB9A 2270/4885NPC1 302/4885SMN1; SMN2 4457/4885 |
| US-11629125-B2 | Elimination of hepatitis b virus with antiviral agents | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
| US-10752584-B2 | Elimination of hepatitis B virus with antiviral agents | HAVCR2, SLC10A1, ABCB11 | RAB9A 1252/4885NPC1 32/4885SMN1; SMN2 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.